These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 23046583)

  • 1. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
    Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
    Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FUS pathology in basophilic inclusion body disease.
    Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
    Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
    Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
    Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
    Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
    Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.
    Troakes C; Hortobágyi T; Vance C; Al-Sarraj S; Rogelj B; Shaw CE
    Neuropathol Appl Neurobiol; 2013 Aug; 39(5):553-61. PubMed ID: 22934812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An autopsied case of sporadic adult-onset amyotrophic lateral sclerosis with FUS-positive basophilic inclusions.
    Matsuoka T; Fujii N; Kondo A; Iwaki A; Hokonohara T; Honda H; Sasaki K; Suzuki SO; Iwaki T
    Neuropathology; 2011 Feb; 31(1):71-6. PubMed ID: 20573033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
    Lashley T; Rohrer JD; Bandopadhyay R; Fry C; Ahmed Z; Isaacs AM; Brelstaff JH; Borroni B; Warren JD; Troakes C; King A; Al-Saraj S; Newcombe J; Quinn N; Ostergaard K; Schrøder HD; Bojsen-Møller M; Braendgaard H; Fox NC; Rossor MN; Lees AJ; Holton JL; Revesz T
    Brain; 2011 Sep; 134(Pt 9):2548-64. PubMed ID: 21752791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.
    Daigle JG; Lanson NA; Smith RB; Casci I; Maltare A; Monaghan J; Nichols CD; Kryndushkin D; Shewmaker F; Pandey UB
    Hum Mol Genet; 2013 Mar; 22(6):1193-205. PubMed ID: 23257289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
    Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
    J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation.
    Suzuki N; Kato S; Kato M; Warita H; Mizuno H; Kato M; Shimakura N; Akiyama H; Kobayashi Z; Konno H; Aoki M
    J Neuropathol Exp Neurol; 2012 Sep; 71(9):779-88. PubMed ID: 22878663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
    Ito D; Suzuki N
    Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations.
    Bäumer D; Hilton D; Paine SM; Turner MR; Lowe J; Talbot K; Ansorge O
    Neurology; 2010 Aug; 75(7):611-8. PubMed ID: 20668261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis.
    Deng HX; Zhai H; Bigio EH; Yan J; Fecto F; Ajroud K; Mishra M; Ajroud-Driss S; Heller S; Sufit R; Siddique N; Mugnaini E; Siddique T
    Ann Neurol; 2010 Jun; 67(6):739-48. PubMed ID: 20517935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological features of FTLD-FUS in a Japanese population: analyses of nine cases.
    Kobayashi Z; Kawakami I; Arai T; Yokota O; Tsuchiya K; Kondo H; Shimomura Y; Haga C; Aoki N; Hasegawa M; Hosokawa M; Oshima K; Niizato K; Ishizu H; Terada S; Onaya M; Ikeda M; Oyanagi K; Nakano I; Murayama S; Akiyama H; Mizusawa H
    J Neurol Sci; 2013 Dec; 335(1-2):89-95. PubMed ID: 24050818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stepwise acquirement of hallmark neuropathology in FUS-ALS iPSC models depends on mutation type and neuronal aging.
    Japtok J; Lojewski X; Naumann M; Klingenstein M; Reinhardt P; Sterneckert J; Putz S; Demestre M; Boeckers TM; Ludolph AC; Liebau S; Storch A; Hermann A
    Neurobiol Dis; 2015 Oct; 82():420-429. PubMed ID: 26253605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease.
    Neumann M; Roeber S; Kretzschmar HA; Rademakers R; Baker M; Mackenzie IR
    Acta Neuropathol; 2009 Nov; 118(5):605-16. PubMed ID: 19669651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
    Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
    Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spectrum and severity of FUS-immunoreactive inclusions in the frontal and temporal lobes of ten cases of neuronal intermediate filament inclusion disease.
    Armstrong RA; Gearing M; Bigio EH; Cruz-Sanchez FF; Duyckaerts C; Mackenzie IR; Perry RH; Skullerud K; Yokoo H; Cairns NJ
    Acta Neuropathol; 2011 Feb; 121(2):219-28. PubMed ID: 20886222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.
    Page T; Gitcho MA; Mosaheb S; Carter D; Chakraverty S; Perry RH; Bigio EH; Gearing M; Ferrer I; Goate AM; Cairns NJ; Thorpe JR
    J Mol Neurosci; 2011 Nov; 45(3):409-21. PubMed ID: 21603978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.